Turnstone Biologics (NASDAQ:TSBX – Get Free Report) and Inhibikase Therapeutics (NYSE:IKT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Turnstone Biologics and Inhibikase Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Turnstone Biologics | 1 | 1 | 0 | 0 | 1.50 |
| Inhibikase Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Turnstone Biologics currently has a consensus price target of $0.45, suggesting a potential downside of 7.52%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 178.97%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Turnstone Biologics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Turnstone Biologics | $19.31 million | 0.58 | -$55.20 million | ($3.24) | -0.15 |
| Inhibikase Therapeutics | $260,000.00 | 621.57 | -$19.03 million | ($2.67) | -0.87 |
Inhibikase Therapeutics has lower revenue, but higher earnings than Turnstone Biologics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Turnstone Biologics and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Turnstone Biologics | N/A | -105.99% | -87.27% |
| Inhibikase Therapeutics | N/A | -350.63% | -201.82% |
Volatility and Risk
Turnstone Biologics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
Institutional & Insider Ownership
52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Turnstone Biologics beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.
About Turnstone Biologics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
